Recent developments in the management of recurrent Clostridioides difficile infection

被引：6
作者：
Mendo-Lopez, Rafael [1 ]
Villafuerte-Galvez, Javier [1 ]
White, Nicole [2 ]
Mahoney, Monica, V [3 ]
Kelly, Ciaran P. [1 ,4 ]
Alonso, Carolyn D. [2 ,4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA
[3] Beth Israel Deaconess Med Ctr, Dept Pharm, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
ANAEROBE | 2020年 / 62卷
基金：
美国国家卫生研究院;
关键词：
Clostridioides difficile infection; Recurrence; Prophylaxis; Antibiotics; Bacteriotherapy; FECAL MICROBIOTA TRANSPLANTATION; DOUBLE-BLIND; VANCOMYCIN PROPHYLAXIS; ORAL VANCOMYCIN; PREVENTION; FIDAXOMICIN; GUIDELINES; EFFICACY; PHASE-2; ADULTS;
D O I：
10.1016/j.anaerobe.2019.102108
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Clostridioides (formerly Clostridium) difficile is responsible for a substantial burden of nosocomial infection. Recurrent C. difficile infection (rCDI) remains a concern due to its high morbidity, mortality, and cost. Despite the updated 2017 IDSA C. difficile treatment guidelines, there remains a lack of well-studied preventive control measures and treatment modalities for rCDI. There are ongoing efforts to develop novel therapies, such as new antibiotics with a lesser impact on gut microbiota and more targeted therapies, such as bacteriotherapy. This mini review highlights key rCDI management updates, preventive measures and ongoing research on novel treatment strategies including bacteriotherapy. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数：8
相关论文
共 44 条
  • [21] Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prevot 1938
    Lawson, Paul A.
    Citron, Diane M.
    Tyrrell, Kerin L.
    Finegold, Sydney M.
    [J]. ANAEROBE, 2016, 40 : 95 - 99
  • [22] Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial
    Lee, Christine H.
    Patino, Hernando
    Stevens, Chris
    Rege, Shruta
    Chesnel, Laurent
    Louie, Thomas
    Mullane, Kathleen M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (10) : 2964 - 2971
  • [23] Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMoa1408913, 10.1056/NEJMc1505190]
  • [24] Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection
    Louie, Thomas
    Nord, Carl Erik
    Talbot, George H.
    Wilcox, Mark
    Gerding, Dale N.
    Buitrago, Martha
    Kracker, Hilke
    Charef, Pascal
    Cornely, Oliver A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6266 - 6273
  • [25] Fidaxomicin versus Vancomycin for Clostridium difficile Infection
    Louie, Thomas J.
    Miller, Mark A.
    Mullane, Kathleen M.
    Weiss, Karl
    Lentnek, Arnold
    Golan, Yoav
    Gorbach, Sherwood
    Sears, Pamela
    Shue, Youe-Kong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05) : 422 - 431
  • [26] Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
    Lowy, Israel
    Molrine, Deborah C.
    Leav, Brett A.
    Blair, Barbra M.
    Baxter, Roger
    Gerding, Dale N.
    Nichol, Geoffrey
    Thomas, William D., Jr.
    Leney, Mark
    Sloan, Susan
    Hay, Catherine A.
    Ambrosino, Donna M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (03) : 197 - 205
  • [27] Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials
    Madoff, Sarah E.
    Urquiaga, Mariana
    Alonso, Carolyn D.
    Kelly, Ciaran P.
    [J]. ANAEROBE, 2020, 61
  • [28] Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials
    Moayyedi, Paul
    Yuan, Yuhong
    Baharith, Harith
    Ford, Alexander C.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2017, 207 (04) : 166 - 172
  • [29] A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
    Mullane, Kathleen M.
    Winston, Drew J.
    Nooka, Ajay
    Morris, Michele I.
    Stiff, Patrick
    Dugan, Michael J.
    Holland, Henry
    Gregg, Kevin
    Adachi, Javier A.
    Pergam, Steven A.
    Alexander, Barbara D.
    Dubberke, Erik R.
    Broyde, Natalya
    Gorbach, Sherwood L.
    Sears, Pamela S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 (02) : 196 - 203
  • [30] Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
    Orenstein, Robert
    Dubberke, Erik
    Hardi, Robert
    Ray, Arnab
    Mullane, Kathleen
    Pardi, Darrell S.
    Ramesh, Mayur S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 (05) : 596 - 602
12345